There are currently 56 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Autism participants are Texas, California, Florida and New York.
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
NCT04648254
Recruiting
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/29/2023
Locations: University of Southern California, Los Angeles, California +3 locations
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer
Register for Updates
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
NCT05060432
Recruiting
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: University of California San Diego, San Diego, California +40 locations
Conditions: Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
Register for Updates
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272
Recruiting
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced sol... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona +18 locations
Conditions: Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Register for Updates
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
NCT04321954
Recruiting
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
Gender:
All
Ages:
18 years and above
Trial Updated:
11/01/2023
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Differentiated Thyroid Cancer, Advanced Cancer
Register for Updates
A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors
NCT04861987
Recruiting
This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Processa Clinical Site, Omaha, Nebraska +5 locations
Conditions: Advanced Cancer, Refractory Cancer, Tumor Gastric
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistanc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Loma Linda University Medical Center, Loma Linda, California +90 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT05500508
Recruiting
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/18/2023
Locations: Mayo Clinic - Arizona, Phoenix, Arizona +6 locations
Conditions: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Register for Updates
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03129139
Recruiting
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +6 locations
Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Register for Updates
Care Planning Framework in Advanced Cancer (ABC123)
NCT05408507
Recruiting
Pilot study assessing the feasibility and acceptability of the ABC123 framework, as well as goal concordance between patient and clinician stated goals. Patients >60 years old with recently diagnosed advanced, incurable cancer in for a first consultation at a participating medical oncology clinic. The team will pilot test the ABC123 framework delivery by an advanced practice provider working with a medical oncologist to inform the overall care planning process. This framework will routinely inco... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
09/19/2023
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Advanced Cancer
Register for Updates
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
NCT05375994
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: UCSF Thoracic Oncology, San Francisco, California +7 locations
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
Register for Updates
Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818
Recruiting
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 in subjects with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Stern Center for Cancer Clinical Trials and Research, Orange, California +18 locations
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Register for Updates
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
NCT05166694
Recruiting
The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions for participants. A PTC is a clinical that will test your genes to gather information about your health that may help guide prescribing advice and offer you new information about your prescriptions. Do... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/14/2023
Locations: University of Chicago Medicine, Chicago, Illinois
Conditions: Cancer, Advanced Cancer, Advanced Solid Tumor, Mental Health Issue, Behavior Disorders
Register for Updates